https://transhumanist.ru/index.php?action=history&feed=atom&title=MENT 2026-09-14T23:10:07Z История изменений этой страницы в вики MediaWiki 1.43.6 https://transhumanist.ru/index.php?title=MENT&diff=5394&oldid=prev 2021-05-12T13:42:05Z

<p>Новая страница: «MENT precursor (Methylated in normal thymocytes protein) [C1orf56] [UNQ547/PRO1104] ==Publications== {{medline-entry |title=Bone and muscle protective potential...»</p> <p><b>Новая страница</b></p><div>MENT precursor (Methylated in normal thymocytes protein) [C1orf56] [UNQ547/PRO1104]<br /> <br /> ==Publications==<br /> <br /> {{medline-entry<br /> |title=Bone and muscle protective potential of the prostate-sparing synthetic androgen 7alpha-methyl-19-nortestosterone: evidence from the aged orchidectomized male rat model.<br /> |pubmed-url=https://pubmed.ncbi.nlm.nih.gov/15784189<br /> |abstract=This study reports the preclinical evaluation of the bone and muscle protective potential of the synthetic androgen 7alpha-methyl-19-nortestosterone ([[MENT]]trade mark), as assessed in the aged orchidectomized rat model. Aged (13-month-old) orchidectomized Wistar rats were treated with different doses of [[MENT]] (4, 12 or 36 microg/day) subcutaneously for 16 weeks via mini-osmotic pumps. Analysis of the effects of androgen deficiency versus [[MENT]] replacement was performed using quantitative computed tomography (pQCT), dual energy X-ray absorptiometry (DEXA) and biochemical markers of bone turnover. At the end of the study period, prostate weight in orchidectomized rats treated with low- (4 microg/day) or mid-dose (12 mug/day) [[MENT]] remained significantly lower compared to the sham-operated animals (-47% and -25%, respectively). High-dose [[MENT]] (36 microg/day), on the other hand, induced prostate hypertrophy ( 21% versus sham). Low-, mid- and high-dose [[MENT]] were found to be effective in suppressing the acceleration of bone remodeling following orchidectomy, as assessed by osteocalcin and deoxypyridinoline. In addition, low-, mid- and high-dose were able to prevent the orchidectomy-induced bone loss, as evaluated by DEXA at the femur and total-body and by pQCT at the femur. Compared to sham-operated animals, the low- and mid-dose [[MENT]] groups showed no decline in lean body mass and no muscle atrophy (as measured by m. quadriceps weight) at 16 weeks, whereas high-dose [[MENT]] was associated with a significant decline in lean body mass (-8.5% versus sham) and quadriceps weight (-10.6%). We conclude that, in the aged orchidectomized rat model, low- and mid-doses of the synthetic androgen [[MENT]] have bone and muscle protective effects and do not induce prostate hypertrophy. The bone protective action of high-dose [[MENT]], however, occurs at the expense of muscle wasting and prostate hypertrophy. Our findings support the need for human studies to explore the potential of [[MENT]] as an option for androgen replacement in aging men.<br /> |mesh-terms=* Absorptiometry, Photon<br /> * Aging<br /> * Animals<br /> * Body Composition<br /> * Bone and Bones<br /> * Estrenes<br /> * Male<br /> * Models, Animal<br /> * Muscle, Skeletal<br /> * Muscular Atrophy<br /> * Orchiectomy<br /> * Rats<br /> * Rats, Wistar<br /> * Tomography, X-Ray Computed<br /> <br /> |full-text-url=https://sci-hub.do/10.1016/j.bone.2005.01.003<br /> }}</div>

OdysseusBot